The Drug Enforcement Administration (DEA) has finalized a one-year extension of telehealth prescribing flexibilities for controlled substances, extending the policy through December 31, 2025. This extension allows healthcare providers to continue prescribing Schedule II-V controlled substances via telehealth without requiring an in-person visit. The decision was made in response to the ongoing need for accessible healthcare and to ensure a smooth transition for patients and providers who have come to rely on telehealth services.
Posted In: Resource Information